// PHARMACOLOGY Questions
// Auto-generated from questions.ts
// Total Questions: 13

import { Question } from '../types';

export const questions: Question[] = [
{
    id: "neet-pg-2024-25",
    subjectId: "pharmacology",
    chapterId: "neet-pg-2024",
    question: "A 76-year-old elderly patient presents in a confused state. He is on antihypertensive\nmedication and on aspirin due to a previous heart attack. There is a minor trauma due\nto fall from a chair 3 weeks back. NCCT is done and shows the following. Diagnosis?",
    options: [
      "SAH (Subarachnoid Hemorrhage)",
      "EDH (Epidural Hematoma)",
      "Normal Study",
      "Chronic SDH (Subdural Hematoma)"
    ],
    correctAnswer: 3,
    explanation: "‚úÖ ANSWER: **Chronic Subdural Hematoma (SDH) (Option D)**\n\nüî¨ DETAILED EXPLANATION:\n\n**Chronic Subdural Hematoma (SDH)** is a collection of **old blood** in the **subdural space** (between dura and arachnoid), occurring **weeks to months** after minor head trauma, most commonly in **elderly** patients.\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüìå TYPES OF INTRACRANIAL HEMORRHAGE:\n\n**ACUTE SDH** (0-3 days):\n‚Ä¢ **Hyperdense** (bright) on CT\n‚Ä¢ **Crescent-shaped** ‚≠ê\n‚Ä¢ Crosses suture lines\n‚Ä¢ Severe trauma usually\n\n**SUBACUTE SDH** (3-21 days):\n‚Ä¢ **Isodense** (same as brain)\n‚Ä¢ May be missed on CT\n\n**CHRONIC SDH** ‚≠ê‚≠ê‚≠ê **(THIS CASE)**\n‚Ä¢ **Hypodense** (dark) on CT ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **>3 weeks** after trauma\n‚Ä¢ **Crescent-shaped**\n‚Ä¢ **Elderly**, **alcoholics**, **anticoagulated** patients\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüéØ RISK FACTORS FOR CHRONIC SDH:\n\n**HIGH RISK:**\n\n‚Ä¢ **Age >65 years** ‚≠ê‚≠ê‚≠ê (brain atrophy ‚Üí bridging veins stretched)\n‚Ä¢ **Anticoagulation** (aspirin, warfarin, NOACs) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Antiplatelet therapy** (aspirin, clopidogrel) ‚≠ê\n‚Ä¢ **Alcohol abuse** (brain atrophy, coagulopathy)\n‚Ä¢ **Dementia** (brain atrophy)\n‚Ä¢ **Falls** (minor trauma sufficient)\n\n**MECHANISM:**\n‚Ä¢ **Brain atrophy** ‚Üí ‚Üë subdural space\n‚Ä¢ **Bridging veins** stretched and fragile\n‚Ä¢ **Minor trauma** tears vein\n‚Ä¢ **Slow bleeding** into subdural space\n‚Ä¢ Blood **liquefies** over weeks (fibrinolysis)\n‚Ä¢ ‚Üí **Hypodense** appearance\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüî¨ CLINICAL PRESENTATION:\n\n**TIMELINE:** Symptoms **weeks to months** after trauma ‚≠ê\n\n**CLASSIC TRIAD** (often incomplete):\n‚Ä¢ **Confusion/altered mental status** ‚≠ê‚≠ê‚≠ê (most common)\n‚Ä¢ **Headache** (gradual onset)\n‚Ä¢ **Gait disturbance/ataxia**\n\n**OTHER SYMPTOMS:**\n‚Ä¢ **Cognitive decline** (mimics dementia)\n‚Ä¢ **Hemiparesis** (focal weakness)\n‚Ä¢ **Seizures**\n‚Ä¢ **Speech difficulties**\n‚Ä¢ **Personality changes**\n‚Ä¢ **Urinary incontinence**\n\n**PRESENTATION IN THIS CASE:**\n‚Ä¢ **76-year-old** ‚úì (elderly)\n‚Ä¢ **Antihypertensive + aspirin** ‚úì (antiplatelet)\n‚Ä¢ **Minor trauma 3 weeks ago** ‚úì (chronic timeframe)\n‚Ä¢ **Confusion** ‚úì (classic symptom)\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüìã CT FINDINGS:\n\n**CHRONIC SDH:**\n‚Ä¢ **Hypodense** (darker than brain) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Crescent-shaped** (follows brain contour)\n‚Ä¢ **Crosses suture lines** (unlike epidural)\n‚Ä¢ May have **fluid-fluid level** (rebleeding)\n‚Ä¢ **Mass effect** (midline shift)\n‚Ä¢ **Bilateral** in 25%\n\n**vs ACUTE SDH:**\n‚Ä¢ **Hyperdense** (brighter than brain)\n‚Ä¢ Recent trauma\n\n**vs SUBDURAL HYGROMA:**\n‚Ä¢ **CSF-density** (very hypodense)\n‚Ä¢ No blood products\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\n‚ùå WHY OTHER OPTIONS ARE INCORRECT:\n\n**A. Subarachnoid Hemorrhage (SAH)** ‚ùå\n\n‚Ä¢ **Sudden severe headache** (\"thunderclap\") ‚≠ê\n‚Ä¢ \"**Worst headache of life**\"\n‚Ä¢ CT shows:\n  ‚Üí **Blood in subarachnoid spaces** (sulci, cisterns)\n  ‚Üí **Star-shaped** around brain\n  ‚Üí **NOT crescent-shaped**\n‚Ä¢ Acute onset (not 3 weeks)\n‚Ä¢ Usually from **aneurysm rupture**\n\n**B. Epidural Hematoma (EDH)** ‚ùå\n\n‚Ä¢ **Biconvex/lens-shaped** ‚≠ê‚≠ê‚≠ê (NOT crescent)\n‚Ä¢ **Does NOT cross suture lines** ‚ö†Ô∏è\n‚Ä¢ **High-impact trauma** (usually)\n‚Ä¢ **Middle meningeal artery** tear\n‚Ä¢ **Lucid interval** classic (but not always)\n‚Ä¢ **Hyperdense** (acute blood)\n‚Ä¢ Younger patients typically\n\n**C. Normal Study** ‚ùå\n\n‚Ä¢ Patient is **confused** with **trauma history**\n‚Ä¢ **Anticoagulated** (aspirin)\n‚Ä¢ **Must have pathology** to explain symptoms\n‚Ä¢ Chronic SDH would show **hypodense crescent**\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüíä MANAGEMENT:\n\n**INDICATIONS FOR SURGERY:**\n‚Ä¢ **Symptomatic** (confusion, weakness)\n‚Ä¢ **>10 mm thickness**\n‚Ä¢ **Midline shift >5 mm**\n‚Ä¢ **Mass effect**\n\n**SURGICAL OPTIONS:**\n\n**1. BURR HOLE DRAINAGE** ‚≠ê‚≠ê‚≠ê (Most common)\n‚Ä¢ Simple, quick procedure\n‚Ä¢ Drill burr hole(s)\n‚Ä¢ Drain liquefied blood\n‚Ä¢ **Subdural drain** left 24-48 hrs\n‚Ä¢ **Success rate 70-90%**\n\n**2. CRANIOTOMY** (if organized/septated)\n‚Ä¢ Larger opening\n‚Ä¢ Remove membranes\n‚Ä¢ For complex/recurrent cases\n\n**MEDICAL MANAGEMENT:**\n‚Ä¢ **Stop anticoagulation** (if safe)\n‚Ä¢ **Reverse coagulopathy**\n‚Ä¢ **Monitor** (if small, asymptomatic)\n\n**RECURRENCE:**\n‚Ä¢ **10-30%** recurrence rate\n‚Ä¢ May need repeat drainage\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüí° KEY POINT FOR EXAM:\n\n**Chronic SDH = Elderly + Minor trauma + Weeks later + Confusion + Hypodense crescent** ‚≠ê‚≠ê‚≠ê\n\n**Remember:** \"**C**hronic SDH is **D**ark (**H**ypodense) on CT!\"\n\n**Classic scenario:**\n‚Ä¢ **Elderly patient** (brain atrophy)\n‚Ä¢ **Anticoagulation/antiplatelet** (aspirin) ‚≠ê\n‚Ä¢ **Minor trauma** (even trivial/forgotten)\n‚Ä¢ **Delayed presentation** (3 weeks in this case) ‚≠ê\n‚Ä¢ **Gradual confusion** (not acute)\n\n**CT:** **Hypodense crescent** (darker than brain)\n\n**Treatment:** **Burr hole drainage** (simple, effective)",
    difficulty: "medium",
    imageUrl: "/images/questions/page10_img24.jpg",
    year: 2024
  },{
    id: "neet-pg-2023-64",
    subjectId: "pharmacology",
    chapterId: "neet-pg-2023",
    question: "P A bronchial asthma patient on inhalational steroids presented with white patchy lesions on the tongue and buccal mucosa. What is the drug that can be used to treat this condition?",
    options: [
      "Clotrimazole",
      "Griseofulvin",
      "Terbinafine",
      "Flucytosine",
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Clotrimazole (Option A)**\n\nüî¨ **ORAL CANDIDIASIS (Thrush):**\n\n**CAUSE (THIS CASE):**\n‚Ä¢ **Inhalational steroids** ‚≠ê‚≠ê‚≠ê (local immunosuppression)\n\n**CLINICAL:**\n‚Ä¢ **White patches** (tongue, buccal mucosa) ‚≠ê\n‚Ä¢ **Can be scraped off** (pseudomembranous)\n‚Ä¢ **Painless** or sore\n\n**TREATMENT:**\n\n**1. Clotrimazole** ‚≠ê‚≠ê‚≠ê **(ANSWER)**\n‚Ä¢ **Topical** (lozenges, oral paint)\n‚Ä¢ **First-line** for oral candidiasis\n\n**2. Nystatin** (oral suspension)\n\n**3. Fluconazole** (systemic, if severe)\n\n**PREVENTION:**\n‚Ä¢ **Rinse mouth** after inhaler use ‚≠ê\n‚Ä¢ **Use spacer**\n\n**WHY NOT OTHERS:**\n‚Ä¢ **Griseofulvin:** Dermatophytes only\n‚Ä¢ **Terbinafine:** Dermatophytes\n‚Ä¢ **Flucytosine:** Systemic, rarely used\n\nüí° **KEY:** **Inhaled steroids + White patches = Oral candidiasis ‚Üí Clotrimazole** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/2023/page31_img18.jpeg",
    year: 2023
  },{
    id: "neet-pg-2023-66",
    subjectId: "pharmacology",
    chapterId: "neet-pg-2023",
    question: "L A pregnant woman with a history of bronchial asthma is in the third stage of labor. Which drugs should be avoided in managing postpartum hemorrhage in this mother?",
    options: [
      "Carboprost",
      "Oxytocin",
      "Dinoproston r",
      "MPethyl ergometrine",
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Carboprost (Option A)**\n\nüî¨ **PPH MANAGEMENT IN ASTHMATIC PATIENT:**\n\n**AVOID:** **Carboprost (PGF2Œ±)** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Contraindicated in asthma** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Causes bronchospasm** (prostaglandin effect)\n\n**SAFE OPTIONS:**\n\n**1. Oxytocin** ‚≠ê (first-line, safe)\n‚Ä¢ **IV infusion** 20-40 units in 1L NS\n\n**2. Misoprostol** (PGE1)\n‚Ä¢ **Safe in asthma**\n\n**3. Methylergometrine** (with caution)\n‚Ä¢ **Safe in asthma**\n‚Ä¢ **Avoid in hypertension**\n\n**WHY CARBOPROST AVOIDED:**\n‚Ä¢ **PGF2Œ±** ‚Üí **Smooth muscle contraction** ‚Üí **Bronchospasm** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ Can cause **severe asthma exacerbation**\n\nüí° **KEY:** **PPH in asthmatic = AVOID Carboprost** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },{
    id: "neet-pg-2023-68",
    subjectId: "pharmacology",
    chapterId: "neet-pg-2023",
    question: "Name the drug that acts on both the marked areas. r e d d a",
    options: [
      "Sacubitril",
      "Omapatrilat p",
      "Losartan e",
      "Nesiritide",
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Omapatrilat (Option B)**\n\nüî¨ **DUAL ACTION DRUGS:**\n\n**OMAPATRILAT:** **Dual inhibitor** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **ACE inhibitor** ‚≠ê\n‚Ä¢ **NEP (neutral endopeptidase) inhibitor** ‚≠ê\n\n**IMAGE (LIKELY):** Shows **ACE** and **NEP** sites\n\n**MECHANISM:**\n‚Ä¢ **Blocks ACE** ‚Üí ‚Üì Angiotensin II, ‚Üì BP\n‚Ä¢ **Blocks NEP** ‚Üí ‚Üë Natriuretic peptides (ANP/BNP), ‚Üì BP\n\n**ISSUE:** **Withdrawn** due to **angioedema** risk ‚≠ê\n\n**MODERN ALTERNATIVE:**\n‚Ä¢ **Sacubitril/Valsartan (Entresto)** ‚≠ê\n  - **NEP inhibitor** (sacubitril) + **ARB** (valsartan)\n  - Used in **heart failure**\n\n**WHY NOT OTHERS:**\n‚Ä¢ **Sacubitril:** NEP only\n‚Ä¢ **Losartan:** ARB only\n‚Ä¢ **Nesiritide:** BNP analog\n\nüí° **KEY:** **Omapatrilat = ACE + NEP inhibitor** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/2023/page33_img19.jpeg",
    year: 2023
  },{
    id: "neet-pg-2023-71",
    subjectId: "pharmacology",
    chapterId: "neet-pg-2023",
    question: "A patient with a previous history of myocardial infarction and ventricular arrhythmia is on treatment for a few months. He developed fatigue, dyspnea, and weight gain. He had also developed pulmonary fibrosis. Which of the following drugs is responsible for the side effects mentioned above?",
    options: [
      "Amiodarone",
      "Atenolol e",
      "Aspirin",
      "Spironolactone",
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Amiodarone (Option A)**\n\nüî¨ **AMIODARONE TOXICITY:**\n\n**INDICATION (THIS CASE):**\n‚Ä¢ **Ventricular arrhythmia post-MI** ‚≠ê\n\n**SIDE EFFECTS (THIS CASE):**\n\n**1. Pulmonary fibrosis** ‚≠ê‚≠ê‚≠ê **(MOST SERIOUS)**\n‚Ä¢ **Dyspnea**, **dry cough**\n‚Ä¢ **Restrictive lung disease**\n‚Ä¢ **Monitor:** Pulmonary function tests, CXR\n\n**2. Hypothyroidism** ‚≠ê\n‚Ä¢ **Fatigue**, **weight gain**\n‚Ä¢ Amiodarone is **37% iodine**\n‚Ä¢ **Monitor:** TSH, T4\n\n**3. Hepatotoxicity** (elevated LFTs)\n\n**4. Corneal deposits** (reversible)\n\n**5. Photosensitivity** (blue-gray skin)\n\n**MONITORING:**\n‚Ä¢ **Baseline:** PFTs, LFTs, TFTs, CXR\n‚Ä¢ **Follow-up:** Every 6 months\n\nüí° **KEY:** **Amiodarone ‚Üí Pulmonary fibrosis + Hypothyroidism** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },{
    id: "neet-pg-2023-73",
    subjectId: "pharmacology",
    chapterId: "neet-pg-2023",
    question: "A young female comes to the emergency department after consuming 100 aspirin tablets. What should be the next step in management?",
    options: [
      "N-acetyl cysteine to replenish glutathione stores",
      "Pralidoxime",
      "Glucagon to control bradycardia and hypoglycemia",
      "Give sodium bicarbonate to alkalize urine",
    ],
    correctAnswer: 3,
    explanation: "‚úÖ ANSWER: **Give sodium bicarbonate to alkalize urine (Option D)**\n\nüî¨ **ASPIRIN OVERDOSE MANAGEMENT:**\n\n**TOXICITY:**\n‚Ä¢ **Salicylism** (tinnitus, vertigo, hearing loss)\n‚Ä¢ **Metabolic acidosis** ‚≠ê\n‚Ä¢ **Respiratory alkalosis** (early)\n‚Ä¢ **Hyperthermia**\n‚Ä¢ **CNS toxicity** (confusion, seizures)\n\n**TREATMENT:**\n\n**1. Urine alkalinization** ‚≠ê‚≠ê‚≠ê **(ANSWER)**\n‚Ä¢ **Sodium bicarbonate IV** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Target urine pH: 7.5-8.5**\n‚Ä¢ **Mechanism:** **Ion trapping** - salicylate is ionized in alkaline urine ‚Üí cannot be reabsorbed ‚Üí ‚Üë excretion ‚≠ê\n\n**2. Activated charcoal** (if <1 hour)\n\n**3. Hemodialysis** (if severe):\n‚Ä¢ **Refractory acidosis**\n‚Ä¢ **Renal failure**\n‚Ä¢ **CNS symptoms**\n‚Ä¢ **Salicylate >100 mg/dL**\n\n**WHY NOT OTHERS:**\n‚Ä¢ **NAC:** Acetaminophen, not aspirin\n‚Ä¢ **Pralidoxime:** Organophosphate\n‚Ä¢ **Glucagon:** Œ≤-blocker overdose\n\nüí° **KEY:** **Aspirin overdose ‚Üí Alkalinize urine (NaHCO‚ÇÉ)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },{
    id: "neet-pg-2023-74",
    subjectId: "pharmacology",
    chapterId: "neet-pg-2023",
    question: "A chronic smoker was on nicotine replacement therapy and clonidine tablets for smoking d de-addiction. He stopped taking clonidine tablets and now presents with a headache. What is the reason behind this condition?",
    options: [
      "Postural hypotension",
      "Receptor upregulation a",
      "Rebound hypertension",
      "Receptor hypersensitivity",
    ],
    correctAnswer: 2,
    explanation: "‚úÖ ANSWER: **Rebound hypertension (Option C)**\n\nüî¨ **CLONIDINE WITHDRAWAL:**\n\n**CLONIDINE:**\n‚Ä¢ **Œ±2-agonist** (central)\n‚Ä¢ **Lowers BP** ‚≠ê\n‚Ä¢ Used for **smoking cessation** ‚≠ê\n\n**SUDDEN WITHDRAWAL** ‚≠ê‚≠ê‚≠ê:\n‚Ä¢ **Rebound hypertension** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Headache** ‚≠ê\n‚Ä¢ **Anxiety**, **tremor**\n‚Ä¢ **Tachycardia**\n‚Ä¢ **Sweating**\n\n**MECHANISM:**\n‚Ä¢ **Suppressed sympathetic activity** rebounds ‚≠ê\n‚Ä¢ **Sudden increase** in catecholamines\n‚Ä¢ **Severe hypertension**\n\n**MANAGEMENT:**\n‚Ä¢ **Restart clonidine** (taper slowly) ‚≠ê\n‚Ä¢ **Antihypertensives** (Œ± + Œ≤ blockers)\n\n**PREVENTION:** **Gradual tapering** ‚≠ê‚≠ê‚≠ê (over 2-4 days)\n\nüí° **KEY:** **Clonidine withdrawal ‚Üí Rebound hypertension** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },{
    id: "neet-pg-2023-76",
    subjectId: "pharmacology",
    chapterId: "neet-pg-2023",
    question: "d A patient with recurrent gout attacks was started on a therapy that inhibits uric acid synthesis. His symptoms were reduced after therapy. Which drug was he started on? d",
    options: [
      "Probenecid",
      "Colchicine",
      "Diclofenac L",
      "Allopurinol p",
    ],
    correctAnswer: 3,
    explanation: "‚úÖ ANSWER: **Allopurinol (Option D)**\n\nüî¨ **GOUT - PROPHYLACTIC THERAPY:**\n\n**MECHANISM:** **Inhibits uric acid synthesis** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Xanthine oxidase inhibitor** ‚≠ê\n‚Ä¢ **Hypoxanthine** ‚Üí ~~Xanthine~~ ‚Üí ~~**Uric acid**~~\n\n**ALLOPURINOL:**\n‚Ä¢ **First-line** for prophylaxis ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Reduces serum uric acid**\n‚Ä¢ **Prevents recurrent attacks**\n\n**INDICATION:**\n‚Ä¢ **Recurrent gout** ‚≠ê\n‚Ä¢ **Tophi**\n‚Ä¢ **Uric acid stones**\n\n**ALTERNATIVE:** **Febuxostat** (newer XO inhibitor)\n\n**WHY NOT OTHERS:**\n‚Ä¢ **Probenecid:** **Increases excretion** (uricosuric)\n‚Ä¢ **Colchicine:** **Acute attack** treatment\n‚Ä¢ **Diclofenac:** **Acute attack** (NSAID)\n\nüí° **KEY:** **Inhibits synthesis = Allopurinol (XO inhibitor)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/2023/page37_img22.jpeg",
    year: 2023
  },{
    id: "neet-pg-2023-77",
    subjectId: "pharmacology",
    chapterId: "neet-pg-2023",
    question: "Sub-Topicr: AP patient with a malignancy is undergoing chemotherapy. The platelet counts were reduced after the previous cycle of chemotherapy. Which of the following drugs can be used to treat th is patient?",
    options: [
      "Oprelvekin (IL-11)",
      "Filgrastim",
      "Erythropoietin",
      "Amifostine",
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Oprelvekin (IL-11) (Option A)**\n\nüî¨ **CHEMOTHERAPY-INDUCED THROMBOCYTOPENIA:**\n\n**DRUG:** **Oprelvekin (Interleukin-11)** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Thrombopoietin agonist**\n‚Ä¢ **Stimulates platelet production** ‚≠ê‚≠ê‚≠ê\n\n**INDICATION:**\n‚Ä¢ **Prevent severe thrombocytopenia** after chemotherapy ‚≠ê\n‚Ä¢ **Reduce need** for platelet transfusions\n\n**SIDE EFFECTS:**\n‚Ä¢ **Fluid retention**\n‚Ä¢ **Arrhythmias**\n‚Ä¢ **Dyspnea**\n\n**WHY NOT OTHERS:**\n‚Ä¢ **Filgrastim (G-CSF):** **Neutropenia** ‚≠ê\n‚Ä¢ **Erythropoietin:** **Anemia** ‚≠ê\n‚Ä¢ **Amifostine:** **Cytoprotective** (reduces toxicity)\n\nüí° **KEY:** **Thrombocytopenia post-chemo ‚Üí Oprelvekin (IL-11)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },{
    id: "neet-pg-2023-78",
    subjectId: "pharmacology",
    chapterId: "neet-pg-2023",
    question: "The true statement among the following is___",
    options: [
      "The dose of telmisartan should be reduced in renal failure but not in hepatic failure.",
      "The dose of irbesartan should be reduced in case of mild-moderate hepatic failure and renal failure. e",
      "The dose of candesartan should be reduced in mild-moderate liver failure but not in renal failure.",
      "Losartan acts as a thromboxane A2 antagonist and inhibits platelet aggregation. d",
    ],
    correctAnswer: 3,
    explanation: "‚úÖ ANSWER: **Losartan acts as a thromboxane A2 antagonist and inhibits platelet aggregation (Option D)**\n\nüî¨ **ARBs - SPECIAL PROPERTIES:**\n\n**LOSARTAN UNIQUE EFFECT:** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Antagonizes thromboxane A2** ‚≠ê\n‚Ä¢ **Inhibits platelet aggregation** ‚≠ê\n‚Ä¢ **Additional cardioprotection**\n\n**DOSE ADJUSTMENTS (ARBs):**\n\n**A. Telmisartan:** FALSE\n‚Ä¢ **Biliary excretion** (97%)\n‚Ä¢ **Reduce in hepatic failure**, NOT renal\n\n**B. Irbesartan:** FALSE\n‚Ä¢ **No adjustment** needed in mild-moderate hepatic/renal failure\n\n**C. Candesartan:** FALSE\n‚Ä¢ **Dual excretion**\n‚Ä¢ **Caution** in both, but no strict reduction\n\n**D. Losartan:** TRUE ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Unique antiplatelet effect**\n\nüí° **KEY:** **Losartan = Only ARB with antiplatelet effect** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/2023/page38_img23.jpeg",
    year: 2023
  },{
    id: "neet-pg-2023-140",
    subjectId: "pharmacology",
    chapterId: "neet-pg-2023",
    question: "A patient given digoxin started having side effects like nausea and vomiting. The serum concentration of digoxin was 4 mg/dL. The plasma therapeutic range is 1 mg/dL. If the half-life of digoxin is 40 hours, how long should one wait before resuming the treatment?",
    options: [
      "40 hours",
      "80 hours",
      "120 hours",
      "140-180 hours",
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **80 hours (Option B)**\n\nüî¨ **DIGOXIN TOXICITY - RESUMPTION CALCULATION:**\n\n**GIVEN:**\n‚Ä¢ **Current level:** 4 mg/dL ‚≠ê\n‚Ä¢ **Therapeutic level:** 1 mg/dL ‚≠ê\n‚Ä¢ **Half-life:** 40 hours ‚≠ê\n‚Ä¢ **Need to reduce:** 4 ‚Üí 1 mg/dL (4-fold reduction)\n\n**HALF-LIFE CALCULATION:**\n\n**After 1 half-life (40 hrs):** 4 ‚Üí 2 mg/dL\n**After 2 half-lives (80 hrs):** 2 ‚Üí 1 mg/dL ‚≠ê‚≠ê‚≠ê **(ANSWER)**\n\n**FORMULA:**\n‚Ä¢ **Number of half-lives** = log‚ÇÇ(Current/Target)\n‚Ä¢ log‚ÇÇ(4/1) = log‚ÇÇ(4) = **2 half-lives**\n‚Ä¢ 2 √ó 40 hours = **80 hours** ‚≠ê‚≠ê‚≠ê\n\n**DIGOXIN TOXICITY FEATURES:**\n‚Ä¢ **GI:** Nausea, vomiting (earliest) ‚≠ê\n‚Ä¢ **Cardiac:** Arrhythmias (any type)\n‚Ä¢ **Visual:** Yellow-green halos\n‚Ä¢ **CNS:** Confusion\n\n**MANAGEMENT:**\n‚Ä¢ **Stop digoxin**\n‚Ä¢ **Correct K+** (hypokalemia worsens toxicity)\n‚Ä¢ **Severe:** Digoxin-specific Fab fragments\n\nüí° **KEY:** **2 half-lives to reduce concentration by 75% (to 1/4)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },{
    id: "neet-pg-2023-141",
    subjectId: "pharmacology",
    chapterId: "neet-pg-2023",
    question: "A patient comes to the casualty with organophosphate poisoning. He was started on atropine infusion and pralidoxime. After 2 hours, the patient had a sudden rise in temperature. What is the likely cause of fever?",
    options: [
      "Atropine toxicity",
      "A side effect of pralidoxime",
      "Due to organophosphate poisoning d",
      "Idiopathic",
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Atropine toxicity (Option A)**\n\nüî¨ **ATROPINE TOXICITY:**\n\n**THIS CASE:**\n‚Ä¢ **OP poisoning** being treated\n‚Ä¢ **Atropine infusion** ‚≠ê\n‚Ä¢ **Sudden fever** after 2 hours ‚≠ê‚≠ê‚≠ê\n\n**ATROPINE SIDE EFFECTS:**\n‚Ä¢ **FEVER/HYPERTHERMIA** ‚≠ê‚≠ê‚≠ê **(ANSWER)**\n  - **Anticholinergic** ‚Üí blocks sweating\n  - **Heat dissipation impaired**\n‚Ä¢ **Dry mouth**, **flushed skin**\n‚Ä¢ **Mydriasis** (dilated pupils)\n‚Ä¢ **Tachycardia**\n‚Ä¢ **Urinary retention**\n‚Ä¢ **Confusion/delirium**\n\n**ATROPINE TOXICITY MNEMONIC:**\n**\"Hot as a hare, Dry as a bone, Red as a beet, Blind as a bat, Mad as a hatter\"** ‚≠ê‚≠ê‚≠ê\n\n**OP POISONING TREATMENT:**\n‚Ä¢ **Atropine** ‚≠ê (reverses muscarinic effects)\n‚Ä¢ **Pralidoxime (PAM)** ‚≠ê (reactivates cholinesterase)\n‚Ä¢ **Decontamination**\n\n**MANAGEMENT:**\n‚Ä¢ **Reduce atropine dose** ‚≠ê\n‚Ä¢ **Cooling measures**\n‚Ä¢ **Monitor vitals**\n\nüí° **KEY:** **Atropine ‚Üí Impaired sweating ‚Üí Hyperthermia** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },{
    id: "neet-pg-2023-143",
    subjectId: "pharmacology",
    chapterId: "neet-pg-2023",
    question: "The mechanism of action of tissue plasminogen activator is",
    options: [
      "Inhibit extrinsic pathway",
      "Inhibits platelet aggregation",
      "Enhance fibrin degradation",
      "Inhibit clot formation",
    ],
    correctAnswer: 2,
    explanation: "‚úÖ ANSWER: **Enhance fibrin degradation (Option C)**\n\nüî¨ **TISSUE PLASMINOGEN ACTIVATOR (tPA):**\n\n**MECHANISM:** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Converts plasminogen ‚Üí plasmin** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Plasmin breaks down fibrin** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ = **Fibrinolysis** (clot breakdown)\n\n**THROMBOLYTIC AGENT** ‚≠ê\n\n**TYPES:**\n‚Ä¢ **Alteplase** (recombinant tPA) ‚≠ê\n‚Ä¢ **Tenecteplase** (TNK-tPA)\n‚Ä¢ **Reteplase** (r-PA)\n\n**INDICATIONS:**\n‚Ä¢ **Acute MI** (ST-elevation) ‚≠ê\n‚Ä¢ **Ischemic stroke** (<4.5 hours) ‚≠ê\n‚Ä¢ **Massive PE**\n\n**CONTRAINDICATIONS:**\n‚Ä¢ **Active bleeding**\n‚Ä¢ **Recent surgery/trauma**\n‚Ä¢ **Hemorrhagic stroke**\n\n**VS OTHER OPTIONS:**\n‚Ä¢ **Inhibit extrinsic pathway:** Warfarin\n‚Ä¢ **Inhibit platelet aggregation:** Aspirin, clopidogrel\n‚Ä¢ **Inhibit clot formation:** Heparin, warfarin\n\nüí° **KEY:** **tPA ‚Üí Plasminogen to Plasmin ‚Üí Fibrin degradation** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  }
];

export default questions;

// Helper function to get questions by chapter
export function getQuestionsByChapter(chapterId: string): Question[] {
  return questions.filter(q => q.chapterId === chapterId);
}

// Export question count
export const questionCount = questions.length;
